In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Improvement in diastolic function and functional class of heart failure with preserved ejection fraction in hypertensive patients: ramipril vs eprosartan

Session Poster session 1 Saturday 08:30 -17:30

Speaker Nadejda Sapojnic

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P241

Authors : N Sapojnic (Chisinau,MD), LF Popescu (Chisinau,MD), AP Caraus (Chisinau,MD)


N Sapojnic1 , LF Popescu1 , AP Caraus1 , 1Institute of Cardiology, Hypertension - Chisinau - Moldova, Republic of ,

European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 49

Purpose: To compare the effect of long-lasting therapy with Ramipril and Eprosartan on diastolic dysfunction (DD) and functional class of heart failure (HF) in hypertensive phenotype of HF with preserved ejection fraction (HFpEF)

Methods: The study enrolled 101 patients with essential hypertension (49,5% men; mean age 50,11 ± 0,79 years) with left ventricular hypertrophy (LVH), DD and preserved ejection fraction (EF>50%). Functional class of HF was evaluated on the basis of a six minute walk test (6MWT). All patients were randomly assigned to treatment with Ramipril (R-gr; n = 56, mean dose=15,3mg±1,2 mg/daily) or Eprosartan (E-gr; n = 45, mean dose=850 ± 12,4 mg/daily), associated to diurietic (Indapamid 1.5 mg/daily). Ambulatory blood pressure monitoring (ABPM), transthoracic echocardiography (TE), and 6MWT were performed at baseline and after 6-,and 12- months of treatment.

Results: Compared to the baseline, there was a statistical improvement in diastolic function after 6 months of treatment in both groups, and this tendency was even more evident at the end of the study: only 20 patients (35,71%) in R-gr and 2 patients (4,44%) in E-gr presented delayed relaxation(DR), (p < 0,001) vs 53 patients (94,64%) in R-gr and 43 patients (95,56%) in E-gr,(p > 0,05) at the beginning of study. At baseline, pseudonormal filling (PsnF) was registered in 3 patients (5,36%) in R-gr and 2 patients (4,44%) in E-gr (p > 0,05),but no patients showed this pattern after 12 months of follow-up period. At this time, normal diastolic filling (NDF) has been noticed in 36 patients (64,29%) in R-gr vs 43 patients (95,56%) in E-gr, (p < 0,001). According to baseline functional disturbances during 6MWT, patients were categorized in functional class of HF (NYHA) as follows: II NYHA-60,7% patients (pts), III NYHA-39,3% pts in R-gr vs 60,00% and 40,00%, respectively, in E-gr (p > 0,05).At 12- month of follow-up examination, 31,5% pts showed I NYHA, 54%-II NYHA, and 14,4%- III NYHA in R-gr vs 42,3%, 49% and 8,6% respectively, in E-gr (p < 0,001).

Conclusion: Both drug-regiment with Ramipril and Eprosartan have shown beneficial effect on diastolic dysfunction and have improved the functional class of heart failure in hypertensive patients, but these improvements were significantly greater in the Eprosartan group.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are